• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

PhotoPharmics Secures $6M for Parkinson’s Light Therapy Trial

by Syed Hamza Sohail 04/21/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

–  PhotoPharmics, a leader in specialized light therapy for neurodegenerative diseases, today announced the close of its oversubscribed $6 million Series B extension. 

–  The round was led by Kickstart Fund with participation from current and new investors, reflecting strong confidence in the company’s clinical promise and the commercial potential of its Parkinson’s therapy.

PhotoPharmics Advances Light-Based Therapy for Parkinson’s with Phase 3 Trial and New Investment

PhotoPharmics, a privately held, clinical-stage medical device company, is pioneering next-generation light-based therapies for neurodegenerative diseases. With over three decades of experience per founder in phototherapy research, the team previously developed circadian-regulating light solutions—now widely used for conditions such as seasonal affective disorder, sleep disturbances, anxiety, and depression—before their acquisition by Philips-Respironics in 2007.

Building on this expertise, the company is developing therapeutic applications of specialized light for a range of neurodegenerative conditions. Its lead innovation, Celeste®, is a disease-targeted light therapy device designed to improve daily functioning in individuals with Parkinson’s disease. Celeste delivers proprietary wavelengths and intensities of light through the eyes to activate neurological pathways, engaging the brain’s natural processes without the systemic side effects of traditional pharmaceuticals.

Celeste is currently undergoing evaluation in the Light for PD Phase 3 clinical trial, which has surpassed 200 participants across the United States. Results from earlier studies have demonstrated significant, clinically meaningful improvements in both motor and non-motor symptoms, including mood, cognition, and sleep quality.

The company recently secured new capital to support the completion of this pivotal trial and to fund key pre-commercialization activities. These efforts will facilitate FDA research completion, strengthen strategic partnerships, and prepare for eventual market launch.

“We’re grateful for the enthusiasm and support of our investors as we move toward the finish line of our clinical program,” said Kent Savage, CEO of PhotoPharmics. “This funding gives us the runway we need to complete our FDA research, build strategic partnerships, and ensure the best possible outcomes for patients.”

Through a novel, non-invasive approach, PhotoPharmics is committed to delivering clinically validated, safe, and effective treatments that improve the lives of patients living with Parkinson’s and other neurodegenerative disorders.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Featured Interview

ConcertAI VP Shares View on AI Hallucinations and the Fabricated Data Crisis in Scientific Publishing

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |